期刊文献+

HIV/HCV共感染患者肝损害影响因素的研究

Risk factors for liver injury in patients with HIV and HCV coinfection
下载PDF
导出
摘要 目的:探讨HIV/HCV共感染患者肝损害影响因素。方法:回顾性分析92例HIV/HCV共感染患者,男51例(55.4%),女41例(44.6%)。年龄9~62岁,平均(39.5±9.4)岁。分别采用单因素及Logistic回归方法分析其肝损害影响因素。结果:单因素分析发现肝损害组20例(33.9%)有抗结核治疗史,39例(66.1%)有抗逆转录病毒治疗史,37例(62.7%)CD4+T淋巴细胞计数<200个/mm3;无肝损害组患者4例(12.1%)有抗结核治疗史,13例(39.4%)有抗逆转录病毒治疗史,14例(42.4%)CD4+T淋巴细胞计数<200个/mm3,统计学分析差异有显著性(P值分别等于0.023、0.013、0.031)。Logistic回归分析提示抗结核治疗和抗逆转录病毒治疗是HIV/HCV共感染患者肝损害的危险因素。结论:HIV/HCV共感染患者肝损害的影响因素是多方面的,其中抗结核治疗和抗逆转录病毒治疗是其独立危险因素。 Objective To explore the risk factors for liver injury in patients with HIV and HCV coinfection. Methods 92 HIV/HCV coinfected patients [51 males and 41 females; aged 9-62 years, mean (39.5 ± 9.4)years] were retrospectively reviewed. The risk factors for liver injury were analyzed by single-variant analysis and multivariant analysis. Results In the group with liver injury, 20 patients (33.9%) had a history of antituberculous therapy, 39 (66.1%) had a history of antiretroviral treatment, and 37 (62.7%) had a CD4 count lower than 200/mm^3; while 4 patients (6.8%) had a history of antitubereulous therapy, 13 (22.0%) had a history of antiretroviral treatment, and 14 (22.7%) had a CD4 count lower than 200/mm^3 in the group without liver injury. The differences between the two groups were significant (P = 0.023, 0.013, and 0.031; respectively). Logistic regression analysis revealed that antituberculous therapy or antiretroviral therapy was an independent risk factor for liver injury in HIV/HCV coinfected patients. Conclusions Of the multiple factors associated with liver injury in patients with HIV and HCV coinfection, antitubercoulous or antiretroviral therapy is an independent risk factor.
出处 《实用医学杂志》 CAS 北大核心 2009年第18期3042-3044,共3页 The Journal of Practical Medicine
基金 北京市科委艾滋病重大项目(编号:D0906003040591) 国家高技术研究发展计划项目(编号:2006AA02Z411) 首都医学发展科研基金项目(编号:2005-2033)
关键词 HIV 肝炎病毒 危险因素 HIV Hepacirirus Risk factors
  • 相关文献

参考文献9

  • 1Alter M J. Epidemiology of viral hepatitis and HIV co-infection [J]. J Hepatol, 2006,44 ( 1 Suppl ) :S6- 89.
  • 2Sulkowski M S, Mehta S H, Torbenson M S, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults [J]. AIDS, 2007,21 (16) : 2209-2216.
  • 3Schiavini M, Angeli E, Mainini A, et al. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002 [J]. HIV Med, 2006,7 (5) : 331-337.
  • 4Feikin D R, Feldman C, Schuchat A, et al. Global strategies to prevent bacterial pneumonia in adults with HIV disease [J]. Lancet Infect Dis, 2004,4(7) :445-455.
  • 5Messou E, Anglaret X, Bonard D, et al. The effect of cotrimoxazole coadministrated with antituberculous drugs on serum transaminases in HIV-infected adults from the Ivory Coast [J]. Br J Clin Pharmacol, 2001,52 (5) : 611-612.
  • 6Kress K D. Antiretroviral-associated hepatotoxicity [J]. Curr Infect Dis Rep, 2005,7(2) : 103-107.
  • 7王江蓉,刘惜年,黄琴,凌云,孙洪清,卢洪洲.血友病合并HIV/HCV感染者肝功能异常的相关因素分析[J].中国艾滋病性病,2006,12(5):415-417. 被引量:2
  • 8Merchante N, Giron-Gonzalez J A, Gonzalez-Serrano M, et al.Survival and prognostic factors of HIV-infeeted patients with HCV- related end-stage liver disease [J].AIDS, 2006,20 ( 1 ) : 49-57.
  • 9Delladetsima J, Katsarou O, Touloumi G, et al. Significance of immune status, genotype and viral load in the severity of chronic hepatitis C in HIV infected haemophilia patients [J]. Haemophilia, 2002,8 (5) : 668-673.

二级参考文献13

  • 1Sherman K,Roustrer S,Chung R,et al.Hepatitis C:prevalence in HIV-infected patients across sectional analysis of the USACTG[J].Antiviral Ther,200,5(Suppl.1):64-65.
  • 2Jhagan H,Thiede H.Sharing ofdrug preparation equipment as a risk factor for hepatitis[J].C Am J Public Health,2001,91:42-46.
  • 3Silva LK,Silva MB,Lopes GB,et al.Prevalence of hepatitis C virus infection and HCV genotypes among hemophiliacs in the State of Bahia,Northeastern Brazil:analysis of serological and virological parameters[J].Rev Soc Bras Med Trop,2005,38(6):496-502.
  • 4Dragoni F,Gentile G,Cartoni C,et al.The role of real-time ultrasonography in predicting esophageal varices in hemophiliacs co-infected with hepatitis C and human immunodeficiency virus[J].Haematologica,2005,90(2):207-213.
  • 5Massimo Puoti,Maurizio Bonacini.Liver Fibrosis Progressioh Is Relatedto CD4Cell Depletion in Patient Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus[J].J Infect Dis,2001,183:134-137.
  • 6Soriano V,Rodriguez-Rosado R,Garcia-Samaniego J.Management of chronic hepatitis C in HIV-infected patients[J].AIDS,1999,13:539-546.
  • 7Gilson RJ,Hawkins AE,Beecham MR,et al.Interactions between HIV and hepatitis B virus in homosexual men:effects on the natural history of infection[J].AIDS,1997,11:597-606.
  • 8Thomas DL,Shih JW,Vlahov D,et al.Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users[J].J Infect Dis,1996,174:690-695.
  • 9Pol S,Fontaine H,Carnot F,et al.The natural history of parenterally-acquired chronic hepatitis C[J].J Hepatol,1998,29:12-20.
  • 10Di Martino V,Thevenot T,Colin JF,et al.Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B[J].Gastroenterology,2002,123:1812-1822.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部